MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/ene.15142

Медицинская библиотека · European journal of neurology · 2021

Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study.

Pontieri Luigi, Blinkenberg Morten, Bramow Stephan, Papp Viktoria, Rasmussen Peter V, Kant Matthias, Schäfer Jakob, Mathiesen Henrik K, Jensen Michael B, Sirakov Georgi, Berg Jonas M, Kopp Tine I, Joensen Hanna, Sellebjerg Finn, Magyari Melinda

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND AND PURPOSE: Real-world evidence regarding the effectiveness and safety of ocrelizumab for the treatment of multiple sclerosis (MS) is limited. The aim was to evaluate the effectiveness and safety of ocrelizumab treatment for MS in a real-world setting.

METHODS

A nationwide population-based cohort study was conducted where clinical and magnetic resonance imaging data of MS patients enrolled prospectively in the Danish Multiple Sclerosis Registry who initiated ocrelizumab treatment between January 2018 and November 2020 were analyzed.

RESULTS

A total of 1104 patients (85.7% relapsing-remitting MS [RRMS], 8.8% secondary progressive MS [SPMS], 5.5% primary progressive MS [PPMS]) were included, with a median follow-up period of 1.3 years. At baseline, the mean age was 41.4 years in the RRMS group, 44.5 years in the PPMS group and 50.3 years in the SPMS group. Median Expanded Disability Status Scale score was 2.5, 3.5 and 5.5, respectively. Most RRMS and SPMS patients had received previous disease-modifying therapies (87.5% and 91.8%, respectively), whereas PPMS patients were mostly treatment naïve (78.7%). After ocrelizumab initiation, 9.3% of the patients experienced a relapse and 8.7% a 24 weeks confirmed disability worsening. Conversely, 16.7% showed a 24 weeks confirmed disability improvement. After ~1 year of treatment, most patients (94.5%) were free of magnetic resonance imaging activity. Ocrelizumab was generally well tolerated, as side effects were only reported for 10% of patients, mostly consisting of infusion-related reactions and infections.

CONCLUSIONS

It is shown that most MS patients treated with ocrelizumab are clinically stabilized and with an adverse event profile consistent with the experience from the pivotal clinical trials.

Для цитирования: Pontieri Luigi, Blinkenberg Morten, Bramow Stephan, Papp Viktoria, Rasmussen Peter V, Kant Matthias, Schäfer Jakob, Mathiesen Henrik K, Jensen Michael B, Sirakov Georgi, Berg Jonas M, Kopp Tine I, Joensen Hanna, Sellebjerg Finn, Magyari Melinda. Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study.. European journal of neurology. 2021. DOI: 10.1111/ene.15142.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.